The purpose of this study is to investigate the effect of THR-1442 compared to Dapagliflozin
as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with
type 2 diabetes mellitus (T2DM).
Approximately 390 subjects with inadequately controlled T2DM on metformin were to be
recruited from China. Subjects were randomly assigned to receive THR-1442 tablet, 20 mg, or
Dapagliflozin tavlet,10 mg, in a ratio of 1:1 once daily for 24 weeks. Subjects were to
continue taking metformin for the duration of the study.
THR-1442 and Dapagliflozin placebo,
Dapagliflozin 10mg and THR1442 placebo
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.